louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01113021: Study of Effects of Low Level Laser Therapy in the Physical Training and the Muscle Responses in Humans.
Official title: Phase 1. Muscle Genic Expression Under Strength Training and Photostimulated by Laser.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Young Male Volunteers
Non Athletes
Free of Metabolic Disease
Joint, Bone and Muscles of Lower Limbs Free of Any Disease
Lead sponsor: Universidade Federal de Sao Carlos
Sponsor class: OTHER
First posted: 2010-04-29
Sex: MALE
Minimum age (years): 18
Maximum age (years): 28
Standard ages: ADULT
Accepts healthy volunteers: yes

Brief summary: The hypothesis of this study is that a chronic program of physical strength

training, associates to effects of low level laser therapy (LLLT) can,

possibly, provide changes in genic expression of muscle and to promote an

enhancement of anaerobic muscle performance in humans.


Eligibility criteria: Inclusion Criteria:

* healthy young male volunteers;
* non-athletic physical activity;
* Body Mass Index (BMI) under 26;
* no prescription medicine or dietary supplement use (such as muscle mass builders.

Exclusion Criteria:

* metabolic disease;
* joint, bone and muscles of lower limbs with any disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: São Carlos
country: Brazil
facility: Federal University of São Carlos
state: São Paulo
Study officials:
References:
citation: Leal Junior EC, Lopes-Martins RA, Dalan F, Ferrari M, Sbabo FM, Generosi RA, Baroni BM, Penna SC, Iversen VV, Bjordal JM. Effect of 655-nm low-level laser therapy on exercise-induced skeletal muscle fatigue in humans. Photomed Laser Surg. 2008 Oct;26(5):419-24. doi: 10.1089/pho.2007.2160.
citation: Leal Junior EC, Lopes-Martins RA, Vanin AA, Baroni BM, Grosselli D, De Marchi T, Iversen VV, Bjordal JM. Effect of 830 nm low-level laser therapy in exercise-induced skeletal muscle fatigue in humans. Lasers Med Sci. 2009 May;24(3):425-31. doi: 10.1007/s10103-008-0592-9. Epub 2008 Jul 23.
citation: Leal Junior EC, Lopes-Martins RA, Baroni BM, De Marchi T, Taufer D, Manfro DS, Rech M, Danna V, Grosselli D, Generosi RA, Marcos RL, Ramos L, Bjordal JM. Effect of 830 nm low-level laser therapy applied before high-intensity exercises on skeletal muscle recovery in athletes. Lasers Med Sci. 2009 Nov;24(6):857-63. doi: 10.1007/s10103-008-0633-4. Epub 2008 Dec 5.
citation: Leal Junior EC, Lopes-Martins RA, Baroni BM, De Marchi T, Rossi RP, Grosselli D, Generosi RA, de Godoi V, Basso M, Mancalossi JL, Bjordal JM. Comparison between single-diode low-level laser therapy (LLLT) and LED multi-diode (cluster) therapy (LEDT) applications before high-intensity exercise. Photomed Laser Surg. 2009 Aug;27(4):617-23. doi: 10.1089/pho.2008.2350.
Clinical trial NCT00799721: Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infant, Very Low Birth Weight
Keywords: ROP
VLBW
Epo
IUGR
VEGF
sFLT-1
very low birth weight infants
retinopathy of prematurity
erythropoietin therapy and risk of ROP
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2008-12-01
Enrollment: 160
Sex: ALL
Maximum age (years): 32
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pretarem infants of less than 32 weeks of gestation or birth weight below 1500g.

Brief summary: VLBW infants are at risk of developing retinopathy of prematurity (ROP). In the first phase of ROP there is a down-regulation of retinal VEGF-expression because of postnatal relative hyperoxia, followed by an upregulation of VEGF mediated through retinal hypoxia, which leads to pathologic vessel formation. VEGF acts through binding to the specific receptor FLT-1, the soluble form sFLT-1 is a specific antagonist of VEGF action. Erythropoietin, given to VLBW infants to prevent anemia, may stimulate VEGF-production in neuronal cells. Currently, there are no data published about VEGF urine-levels in VLBW infants and it is not known, if urine VEGF-levels may serve as a non-invasive marker of ROP-risk. Further shall be investigated, if erythropoietin-therapy increases urine VEGF-levels and if there is a correlation with ROP-development.


Eligibility criteria: Inclusion Criteria:

* gestational age \< 32 weeks
* birth weight \<1500g

Exclusion Criteria:

* absent written consent by parents
* connatal eye malformation

Primary outcomes:
measure: Development of ROP
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité Virchow-Hospital
Study officials:
References:
Clinical trial NCT02714621: MR-HIFU for Recurrent Gynaecological Cancer
Official title: Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU): A Feasibility Study for Treating Recurrent Gynaecological Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Cancer
Endometrial Cancer
Uterine Cancer
Ovarian Cancer
Vaginal Cancer
Vulvar Cancer
Keywords: Magnetic Resonance Imaging (MRI)
High Intensity Focused Ultrasound (HIFU)
Focused Ultrasound Surgery
Lead sponsor: Institute of Cancer Research, United Kingdom
Sponsor class: OTHER
First posted: 2016-03-21
Enrollment: 31
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this pilot study is to determine whether or not it is feasible to use MRgHIFU to treat symptomatic (pain, bleeding) recurrent pelvic malignancy with an acceptable safety profile when conventional treatment options are not available. The ultimate goal is to be able not only to offer a viable method of symptom palliation in patients with recurrent pelvic tumours and improve their quality of life; but also to control tumour growth and extend life in a group of relatively young patients with isolated local recurrence.


Eligibility criteria: Inclusion Criteria:

* Patients with recurrent pelvic gynaecological malignancy (cervix and endometrial cancer).
* Recurrent lesion is painful (NRS\>4) and not suitable for alternative treatments
* Intended target volume accessible for MRgHIFU treatment
* Intended target volume visible on noncontrast MR imaging
* Distance between target and skin ≥1cm

Exclusion Criteria:

* MRI contraindicated (e.g. by incompatible metal implants or claustrophobia)
* Pregnancy
* Sedation contraindicated
* MRI contrast agent contraindicated
* Scar, internal or external fixation device along the beam path or at the target

Primary outcomes:
measure: Changes in pain, measured using a patient diary
timeFrame: 7 days post-treatment, follow up at 90 days
Secondary outcomes:
measure: Changes in bleeding, measured using a questionnaire
timeFrame: 7 days post-treatment, follow up at 90 days
Other outcomes:
Locations:
city: Sutton
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
state: Surrey
Study officials:
References:
citation: Imseeh G, Giles SL, Taylor A, Brown MRD, Rivens I, Gordon-Williams R, Ter Haar G, deSouza NM. Feasibility of palliating recurrent gynecological tumors with MRGHIFU: comparison of symptom, quality-of-life, and imaging response in intra and extra-pelvic disease. Int J Hyperthermia. 2021;38(1):623-632. doi: 10.1080/02656736.2021.1904154.
Clinical trial NCT01781221: Sinus Floor Elevation Using Separately Two Different Xenografts - A Prospective Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Posterior Maxilla Edentulous Patients With Insufficient Alveolar Bone Height
Lead sponsor: University Hospital of Cologne
Sponsor class: OTHER
First posted: 2013-01-31
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the regenerative results of using separately two different xenografts after two-step sinus floor elevation.


Eligibility criteria: Inclusion Criteria:

1. Patients who will present with a moderately or severely atrophic posterior maxilla with 1-6 mm residual alveolar bone .
2. Men and women over the age of 18 years.
3. Patient has signed the Informed Consent.

Exclusion Criteria:

1. Chronic steroid therapy.
2. Uncontrolled diabetes.
3. Cardiovascular disease.
4. Past irradiation of head and neck.
5. Maxillary sinus cysts.
6. Active chronic sinusitis.
7. Smoking more than ten cigarettes per day during the 3 months preceding this study .
8. Malignant disease in the 5 years preceding this study.
9. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia
10. Disease that compromise the immune system
11. Psychiatric disorder
12. Hypersensitivity to titanium, collagen or bovine bone.
13. Women who are pregnant or nursing.
14. Patients with non-treated periodontal disease.
15. Medical and/or general contraindications for intraoral surgical procedures.

Primary outcomes:
measure: Uneventful healing and histological bone formation
timeFrame: 6 months following sinus floor augmentation
Secondary outcomes:
measure: X-ray demonstration of volume - stable results
timeFrame: 6 months following augmentation procedures.
measure: Equally high implant survival rates and crestal bone loss
timeFrame: After 1,2 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02323321: International EXPAND Heart Pivotal Trial
Official title: International Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation (EXPAND Heart Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Transplant
Keywords: heart transplant
heart preservation
beating heart transplant
Lead sponsor: TransMedics
Sponsor class: INDUSTRY
First posted: 2014-12-23
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the effectiveness of the OCS™ Heart to recruit, preserve and assess donor hearts that may not meet current standard donor heart acceptance criteria (as identified above) for transplantation to potentially improve donor heart utilization for transplantation


Eligibility criteria: Inclusion Criteria:

* Registered male or female primary Heart transplant candidate
* Age ≥18 years old

Exclusion Criteria:

* Prior solid organ or bone marrow transplant
* Chronic use of hemodialysis or diagnosis of chronic renal insufficiency
* Multi-organ transplant

Primary outcomes:
measure: Patient Survival at Day-30 Post Transplant and Absence of Severe Primary Heart Graft Dysfunction in the First 24 Hours Post-transplantation
timeFrame: 30 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
city: Indianapolis
country: United States
facility: Indiana University
state: Indiana
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: Grand Rapids
country: United States
facility: Spectrum Health
state: Michigan
city: Minneapolis
country: United States
facility: Minneapolis Heart Institute
state: Minnesota
city: Minneapolis
country: United States
facility: University of Minnesota Medical Center
state: Minnesota
city: New York
country: United States
facility: Mount Sinai
state: New York
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Seattle
country: United States
facility: University of Washington Medical Center
state: Washington
Study officials:
References:
Clinical trial NCT01626521: Value of Prothrombin Fragment F1+2 in the Diagnosis of Pulmonary Embolism in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Obstructive Pulmonary Disease
Pulmonary Embolism
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-06-22
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to hospital due to COPD exacerbation

Brief summary: To access the clinical usefulness of F1+2 in the diagnosis of PE in patients with AECOPD who require hospitalization. Specifically, to determine whether F1+2 may have an additional value in the subgroup of patients with an abnormal D-dimer,to determine whether it may increase the proportion of patients in whom PE can be safely ruled out and to determine the sensitivity, specificity and NPV of F1+2 at various cut-off values.


Eligibility criteria: Inclusion Criteria:

* COPD exacerbation
* Able to give informed consent
* Able to perform spirometry

Exclusion Criteria:

* Known malignancy
* Known hypercoagulable state
* Receiving anticoagulant treatment
* Pregnancy
* Renal failure
* Allergy to iodine

Primary outcomes:
measure: Negative Predictive Value of Prothrombin Fragment F1+2
timeFrame: Six months
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT02229721: Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women
Official title: Female Sexual Dysfunction in the Menopause: Effect of Intranasal Oxytocin Administration on Sexual Function and Activity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Female Sexual Dysfunction
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
Collaborators: name: Leadiant Biosciences, Inc.
First posted: 2014-09-01
Enrollment: 30
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether intranasal oxytocin is effective in comparison to placebo in improving female sexual dysfunction in pre- and postmenopausal women.


Eligibility criteria: Inclusion Criteria:

* Willingness to attempt sexual intercourse and/ or masturbation at least two times per week
* Ongoing relationship for at least 3 months
* Female subjects aging 40 years and more, Male subjects must be older than 18
* The participation in this study should be of free choice to male partners
* Willingness to perform a pregnancy test every month (for pre-menopausal subjects)
* Willingness to use contraception during the study period (for pre-menopausal subjects)
* Normal findings in the urogenital tract unless the investigator considers an abnormality to be clinically irrelevant
* Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant

Exclusion Criteria:

* Primary sexual dysfunction
* sexual abuse
* severe psychiatric diseases
* untreated conditions and medication intake with associated reduction of sexual function.
* In male partners: any severe andrological or related medical problem.

Primary outcomes:
measure: Female Sexual Function
timeFrame: 22 weeks
Secondary outcomes:
measure: Hamilton Depression Scale (HDS)
timeFrame: 22 weeks
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Study officials:
References:
citation: Muin DA, Sheikh Rezaei S, Tremmel-Scheinost M, Salama M, Luger A, Wolzt M, Husslein PW, Bayerle-Eder M. Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study. Fertil Steril. 2017 Mar;107(3):781-787.e3. doi: 10.1016/j.fertnstert.2016.12.003. Epub 2017 Feb 8.
citation: Muin DA, Wolzt M, Marculescu R, Sheikh Rezaei S, Salama M, Fuchs C, Luger A, Bragagna E, Litschauer B, Bayerle-Eder M. Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial. Fertil Steril. 2015 Sep;104(3):715-23.e4. doi: 10.1016/j.fertnstert.2015.06.010. Epub 2015 Jul 4.
Clinical trial NCT02741921: Conventional Double-lumen Tube vs VivaSight DL
Official title: Ability of Anesthesiologist to Placid a Double-lumen Tube. A Randomized Crossover Cadaver Study Comparing VivaSight DL and Conventional Double-lumen Tube
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endotracheal Intubation
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
First posted: 2016-04-18
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The investigators sought to compare the time to intubation and success rate of the endotracheal intubation using standard double-lumen tube and video tube ETView DL in an adult cadaver model in normal and difficult airway conditions.


Eligibility criteria: Inclusion Criteria:

* fresh adult cadavers

Exclusion Criteria:

* cadavers with face injures

Primary outcomes:
measure: Time required for endotracheal intubation
timeFrame: 1 day
Secondary outcomes:
measure: Time required for visual confirmation of double lumen tube position position
timeFrame: 1 day
measure: success rate of intubation attempt
timeFrame: 1 day
measure: Ease of intubation
timeFrame: 1 day
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Medical University of Warsaw, Department of Emergency Medicine
state: Masovia
Study officials:
References:
citation: Kurowski A, Szarpak L, Truszewski Z, Czyzewski L. Can the ETView VivaSight SL Rival Conventional Intubation Using the Macintosh Laryngoscope During Adult Resuscitation by Novice Physicians?: A Randomized Crossover Manikin Study. Medicine (Baltimore). 2015 May;94(21):e850. doi: 10.1097/MD.0000000000000850.
citation: Szarpak L, Kurowski A, Zasko P, Karczewska K, Czyzewski L, Bogdanski L, Adamczyk P, Truszewski Z. Double-lumen tube tracheal intubation in a manikin model using the VivaSight Double Lumen: a randomized controlled comparison with the Macintosh laryngoscope. Am J Emerg Med. 2016 Jan;34(1):103-4. doi: 10.1016/j.ajem.2015.10.018. Epub 2015 Oct 23. No abstract available.
Clinical trial NCT03250221: Comparison of Robot-assisted Laparoscopic Myomectomy and Traditional Laparoscopic Myomectomy With Barbed Sutures
Official title: Comparison of Robot-assisted Laparoscopic Myomectomy and Traditional Laparoscopic Myomectomy With Barbed Sutures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myomectomy
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2017-08-15
Enrollment: 80
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who underwent robotic myomectomy and conventional laparoscopic myomectomy

Brief summary: To elucidate the impact of barbed sutures on robotic myomectomy and laparoscopic myomectomy

Detailed description: The aim of our study will be to elucidate the impact of the use of barbed sutures on robotic myomectomy and laparoscopic myomectomy

Eligibility criteria: Inclusion Criteria:

* All women who underwent robotic myomectomy and conventional laparoscopic myomectomy in the Department of Obstetrics \& Gynecology of Far Eastern Memorial Hospital.

Exclusion Criteria:

* Open myomectomy

Primary outcomes:
measure: Abdominal drainage amount
timeFrame: 1 day
Secondary outcomes:
measure: Blood loss
timeFrame: 1 day
measure: Surgical time
timeFrame: 1 day
Other outcomes:
Locations:
city: Banqiao
country: Taiwan
facility: Far Eastern Memorial Hospital
state: New Taipei
Study officials:
affiliation: Far Eastern Memorial Hospital
name: Sheng-Mou Hsiao, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hsiao SM, Lin HH, Peng FS, Jen PJ, Hsiao CF, Tu FC. Comparison of robot-assisted laparoscopic myomectomy and traditional laparoscopic myomectomy. J Obstet Gynaecol Res. 2013 May;39(5):1024-9. doi: 10.1111/j.1447-0756.2012.02073.x. Epub 2013 Feb 4.
Clinical trial NCT06869421: Awareness of Patients Having Diabetes Mellitus About Oral Health
Official title: Knowledge, Attitude and Awareness of Diabetic Patients on Association Between Oral Health and Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Awareness
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-03-11
Enrollment: 310
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: patients having diabetes mellitus

Brief summary: Diabetic patients will be asked to answer a group of questions about the predictors (age, type of diabetes, level of education) and about the outcomes \[knowledge and awareness of the link between diabetes and oral health, and attitude towards maintaining their oral health as diabetics.

Detailed description: The study will recruit patients having diabetes mellitus; where they will be asked to answer a questionnaire after obtaining an informed consent. Diabetic patients will be asked to answer a group of questions about the predictors (age, type of diabetes, level of education) and about the outcomes knowledge and awareness of the link between diabetes and oral health, and attitude towards maintaining their oral health as diabetics.

Eligibility criteria: Inclusion Criteria:

* aged at least 18 years and being diagnosed with diabetes mellitus

Exclusion Criteria:

* individuals who refuse to participate in the study

Primary outcomes:
measure: knowledge and awareness of the link between diabetes and oral health
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: